Literature DB >> 9276469

Crystal structure of vipoxin at 2.0 A: an example of regulation of a toxic function generated by molecular evolution.

M Perbandt1, J C Wilson, S Eschenburg, I Mancheva, B Aleksiev, N Genov, P Willingmann, W Weber, T P Singh, C Betzel.   

Abstract

Vipoxin is the main toxic component in the venom of the Bulgarian snake Vipera ammodytes meridionalis, the most toxic snake in Europe. Vipoxin is a complex between a toxic phospholipase A2 (PLA2) and a non-toxic protein inhibitor. The structure is of genetic interest due to the high degree of sequence homology (62%) between the two functionally different components. The structure shows that the formation of the complex in vipoxin is significantly different to that seen in many known structures of phospholipases and contradicts the assumptions made in earlier studies. The modulation of PLA2 activity is of great pharmacological interest, and the present structure will be a model for structure-based drug design.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276469     DOI: 10.1016/s0014-5793(97)00853-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Protein complexes in snake venom.

Authors:  R Doley; R M Kini
Journal:  Cell Mol Life Sci       Date:  2009-06-04       Impact factor: 9.261

2.  Asp Viper (Vipera aspis) envenomation: experience of the Marseille Poison Centre from 1996 to 2008.

Authors:  Luc de Haro; Mathieu Glaizal; Lucia Tichadou; Ingrid Blanc-Brisset; Maryvonne Hayek-Lanthois
Journal:  Toxins (Basel)       Date:  2009-11-24       Impact factor: 4.546

3.  Homology modelling of protein-protein complexes: a simple method and its possibilities and limitations.

Authors:  Guillaume Launay; Thomas Simonson
Journal:  BMC Bioinformatics       Date:  2008-10-09       Impact factor: 3.169

4.  Reappraisal of Vipera aspis venom neurotoxicity.

Authors:  Elisabeth Ferquel; Luc de Haro; Virginie Jan; Isabelle Guillemin; Sabine Jourdain; Alexandre Teynié; Jacques d'Alayer; Valérie Choumet
Journal:  PLoS One       Date:  2007-11-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.